Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for magnesium
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical (...) Effectiveness and Guidelines Published on: April 20, 2017 Project Number: RC0873-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of magnesium as an analgesic for the treatment of adult patients with migraine or chronic pain? What are the evidence-based guidelines regarding the use of magnesium as an analgesic in adult patients with migraine or chronic pain? Key Message Definitive conclusions
Magnesium for treating sickle cell disease. Sickle cell disease is an autosomal recessive inherited haemoglobinopathy which causes painful vaso-occlusive crises due to sickle red blood cell dehydration. Vaso-occlusive crises are common painful events responsible for a variety of clinical complications; overall mortality is increased and life expectancy decreased compared to the general population. Experimental studies suggest that intravenous magnesium has proven to be well-tolerated (...) in individuals hospitalised for the immediate relief of acute (sudden onset) painful crisis and has the potential to decrease the length of hospital stay. Some in vitro studies and open studies of long-term oral magnesium showed promising effect on pain relief but failed to show its efficacy. The studies show that oral magnesium therapy may prevent sickle red blood cell dehydration and prevent recurrent painful episodes. There is a need to access evidence for the impact of oral and intravenous magnesium
The role of magnesium sulfate in the intensive care unit Magnesium (Mg) has been developed as a drug with various clinical uses. Mg is a key cation in physiological processes, and the homeostasis of this cation is crucial for the normal function of body organs. Magnesium sulfate (MgSO4) is a mineral pharmaceutical preparation of magnesium that is used as a neuroprotective agent. One rationale for the frequent use of MgSO4 in critical care is the high incidence of hypomagnesaemia in intensive
Inducible expression of magnesium protoporphyrin chelatase subunit I (CHLI)-amiRNA provides insights into cucumber mosaic virus Y satellite RNA-induced chlorosis symptoms Recent studies with Y satellite RNA (Y-sat) of cucumber mosaic virus have demonstrated that Y-sat modifies the disease symptoms in specific host plants through the silencing of the magnesium protoporphyrin chelatase I subunit (CHLI), which is directed by the Y-sat derived siRNA. Along with the development of peculiar yellow
Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensityâ€”AÂ Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification
ACTH, Cortisol and IL-6 Levels in Athletes following Magnesium Supplementation Physical exercise activates the hypothalamo-pituitary-adrenal (HPA) axis and induces the body's inflammatory response. Due to contemporary dietary habits and increased energy expenditure, athletes are susceptible to depletion of magnesium ions. The aim of our study was to investigate, through assessment of plasma ACTH, serum IL-6, and salivary/serum cortisol levels, if chronic magnesium supplementation might reduce (...) damaging stress effects in amateur rugby players.Rugby players (N=23) were randomly assigned to intervention and control group. Basal samples were collected before intervention group started a 4-week-long supplementation with magnesium (500 mg Mg/d). Blood and saliva sampling were done a day before the match (Day-1), on the morning of competition (Game), and during a six-day-long recovery period (Day1, Day3 and Day6). ACTH, serum/salivary cortisol, IL-6 and total/differential leukocytes counts were
The effect of intravenous magnesium sulfate infusion on reduction of pain after abdominal hysterectomy under general anesthesia: a double-blind, randomized clinical trial. Post-surgical pain is a physiological response to tissue trauma that produces unpleasant physiological effects with manifestations on various organic systems.According to the effect of magnesium sulfate on the N-methyl-d-aspartate (NMDA) receptor, this study examined the effect of magnesium sulfate on the reduction of pain (...) of the patients received 5 mg of intravenous morphine 30 min after induction of anesthesia. Afterwards, the study group received 50 mg/kg of magnesium sulfate in 500 cm(3) of Ringer's serum during the 20 minutes, and 500 cm(3) of Ringer's serum was administered to the members of the placebo group. Visual analogue scale VAS scores were evaluated to reach the minimum difference of 0.8 in mean pain score.The results of this study indicated that the mean pain scores immediately after surgery and at 1, 2, 6
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises. We hypothesized that intravenous magnesium would shorten length of stay, decrease opioid use, and improve health-related quality of life (HRQL) for pediatric patients hospitalized with sickle cell pain crises. The Magnesium for Children in Crisis (MAGiC) study (...) was a randomized, double-blind, placebo-controlled trial of intravenous magnesium vs normal saline placebo conducted at 8 sites within the Pediatric Emergency Care Applied Research Network (PECARN). Children 4 to 21 years old with hemoglobin SS or Sβ(0) thalassemia requiring hospitalization for pain were eligible. Children received 40 mg/kg of magnesium or placebo every 8 hours for up to 6 doses plus standard therapy. The primary outcome was length of stay in hours from the time of first study drug infusion
Magnesium Sulfate Use in Obstetrics Magnesium Sulfate Use in Obstetrics - ACOG Menu ▼ Magnesium Sulfate Use in Obstetrics Page Navigation ▼ INTERIM UPDATE Number 652, January 2016 (Replaces Committee Opinion Number 573, September 2013) (Reaffirmed 2018) The American College of Obstetricians and Gynecologists Committee on Obstetric Practice Society for Maternal-Fetal Medicine This document reflects emerging clinical and scientific advances as of the date issued and is subject to change (...) . The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. INTERIM UPDATE: This Committee Opinion is updated to reflect a limited, focused change in gestational age at which to consider tocolysis. Magnesium Sulfate Use in Obstetrics ABSTRACT: The U.S. Food and Drug Administration advises against the use of magnesium sulfate injections for more than 5–7 days to stop preterm labor in pregnant women. Based on this, the drug classification was changed from
Intravenous Magnesium Sulphate for Refractory Torsades de Pointes or Ventricular fibrillation: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Refractory Torsades de Pointes or Ventricular fibrillation: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Intravenous Magnesium Sulphate for Refractory Torsades de Pointes or Ventricular fibrillation: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Refractory Torsades de (...) Pointes or Ventricular fibrillation: Clinical Effectiveness and Guidelines Published on: November 6, 2015 Project Number: RB0928-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of intravenous magnesium sulphate for patients with refractory torsades de pointes or ventricular fibrillation? What are the evidence-based guidelines regarding the administration of intravenous magnesium sulphate for patients
Magnesium aspartate dihydrate (Magnaspartate) Magnesium aspartate dihydrate (Magnaspartate) Magnesium aspartate dihydrate (Magnaspartate) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Magnesium aspartate dihydrate (Magnaspartate) Penarth: All Wales Therapeutics (...) and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2596. 2015 Authors' conclusions Magnesium aspartate dihydrate (Magnaspartate®) is recommended as an option for use within NHS Wales for the treatment and prevention of magnesium deficiency, as diagnosed by a doctor, in adults, children and adolescents aged from two years. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adolescent; Adult
Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical (...) Effectiveness and Guidelines Published on: September 2, 2015 Project Number: RB0906-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of intravenous administration of magnesium sulphate for the treatment of acute and unrelieved, refractory asthma-related bronchospasm in prehospital settings? What are the evidence-based guidelines regarding the intravenous administration of magnesium sulphate for the treatment of acute
Magnesium aspartate dihydrate (Magnaspartate) - for the treatment and prevention of magnesium deficiency Final Appraisal Recommendation Advice No: 2215 – July 2015 Magnesium aspartate dihydrate (Magnaspartate ® ) 243 mg powder for oral solution Limited submission by Kora Healthcare Additional note(s): • Magnaspartate ® is the first licensed oral magnesium product available in Wales for the treatment and prevention of magnesium deficiency. In reaching the above recommendation AWMSG has taken (...) every three years. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2215: Magnesium aspartate dihydrate (Magnaspartate ® ) 243 mg powder for oral solution. July 2015. Recommendation of AWMSG Magnesium aspartate dihydrate (Magnaspartate ® ) is recommended as an option for use within NHS Wales for the treatment and prevention of magnesium deficiency
Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? BestBets: Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? Report By: Dr Peter Kilgour, Dr Babajide Oni - Emergency Medicine ST2 Search checked by Dr Dianne Tabone , Dr Hisham Ghanayem (ST5) - Consultant in Emergency Medicine Preston and (ST5 Central Manchester (...) ) Institution: Royal Preston Hospital, Preston, Lancs, UK Date Submitted: 11th November 2014 Date Completed: 6th May 2015 Last Modified: 6th May 2015 Status: Green (complete) Three Part Question In [patients with a femoral neck fracture] does [magnesium prolong the analgaesic effect of bupivacaine] in [a fascia iliaca nerve block]? Clinical Scenario An 89-year-old woman presents to your emergency department following a fall. She is complaining of severe pain in her right hip area. A plain radiograph shows
Prehospital use of magnesium sulfate as neuroprotection in acute stroke. Magnesium sulfate is neuroprotective in preclinical models of stroke and has shown signals of potential efficacy with an acceptable safety profile when delivered early after stroke onset in humans. Delayed initiation of neuroprotective agents has hindered earlier phase 3 trials of neuroprotective agents.We randomly assigned patients with suspected stroke to receive either intravenous magnesium sulfate or placebo, beginning (...) within 2 hours after symptom onset. A loading dose was initiated by paramedics before the patient arrived at the hospital, and a 24-hour maintenance infusion was started on the patient's arrival at the hospital. The primary outcome was the degree of disability at 90 days, as measured by scores on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability).Among the 1700 enrolled patients (857 in the magnesium group and 843 in the placebo group), the mean (±SD) age
Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations? Systematic Review Snapshot TAKE-HOME MESSAGE Administration of intravenous magnesium sulfate may result in a modest reduction in hospital admissions among adult ED patients with acute asthma who have not responded to standard therapies. Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations? EBEM Commentators (...) intravenous magnesium sulfate during 15 to 30 minutes experienced a small but signi?cant reduction in rates of hospital admission (odds ratio [OR] 0.75), with minimal heterogeneity observed (I 2 ¼28%). When the 3 studies at high or unclear risk of bias for blinding were removed, the pooled effect for hospital admission was similar (OR 0.72; 95% con?dence interval [CI] 0.57 to 0.91). There was no signi?cant change in spirometric parameters (eg, peak expiratory ?ow) as well. All studies included
Intrapartum magnesium sulfate and need for intensive delivery room resuscitation To evaluate the association of intrapartum magnesium sulfate for fetal neuroprotection (MgSO4-FN) with the delivery room resuscitation and neonatal outcomes of preterm infants in an era of minimisation of invasive mechanical ventilation.Retrospective cohort study.Neonatal intensive care units in the Canadian Neonatal Network.Preterm infants (23(0) to 31(6) weeks gestational age) born in 2011 or 2012. Resuscitation